Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
Launched by M.D. ANDERSON CANCER CENTER · Feb 10, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Writing to Heal Study, is exploring how a special writing program can help improve the health of Chinese immigrant women who have survived breast cancer. The program focuses on using culturally relevant writing techniques to allow participants to express their feelings and experiences related to their cancer journey. By participating, the women may gain valuable insights into their health and wellbeing while also helping researchers learn more about the unique challenges faced by this community.
To be eligible for the trial, participants must be foreign-born Chinese women aged 18 or older who have been diagnosed with stage 0 to III breast cancer. They should have completed their primary cancer treatments within the last five years and have lived in the U.S. for at least six months. Participants can expect to engage in writing activities that encourage reflection and sharing about their health experiences. This study is currently looking for volunteers, so if you or someone you know fits the criteria, it could be a meaningful opportunity to contribute to research while supporting personal healing.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Being diagnosed with stage 0-III breast cancer.
- • 2. Completed primary treatment, including surgery, chemotherapy, radiation therapy, immune therapy, and/or targeted therapy within the preceding 5 years.
- • 3. Foreign-born Chinese women (aged 18 and older) who lived in the U.S. for at least six months in the past.
- Exclusion Criteria:
- • 1. Exclusion criteria include inability to provide informed consent
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Qian Lu
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials